microRNA-Based Molecular Diagnostics Company Developing New Cancer Tests
|
By LabMedica International staff writers Posted on 22 Dec 2009 |
|
A microRNA-based molecular diagnostics company has disclosed that it intends to develop and commercialize three new tests for cancer during the next two years.
Rosetta Genomics (Rehovot, Israel) is working to develop the second-generation miRview mets, a test for cancer of unknown primary. The current version of this test has a tumor panel of 25 cancers. The company is designing a test to identify a much larger panel of cancer origins, which it expects to market by the second half of 2010.
After differentiating small-cell lung cancer from non-small-cell lung cancer, a test will further subclassify non-small-cell lung cancer into squamous or nonsquamous. This test is being developed to leverage the company's new Fine Needle Aspirate (FNA) platform technology across several types of tests. The company aims to launch the extended lung cancer diagnostic in the second half of 2011.
The third test being developed by Rosetta Genomics is for bladder cancer. The aim of this test is to predict the risk of superficial bladder cancer becoming invasive. The target date for commercialization is late 2011.
Rosetta Genomics is a developer of microRNA-based molecular diagnostics. Its integrative research platform, combining bioinformatics and state-of-the-art laboratory processes, has led to the discovery of hundreds of biologically validated novel human microRNAs. The company is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools.
Related Links:
Rosetta Genomics
Rosetta Genomics (Rehovot, Israel) is working to develop the second-generation miRview mets, a test for cancer of unknown primary. The current version of this test has a tumor panel of 25 cancers. The company is designing a test to identify a much larger panel of cancer origins, which it expects to market by the second half of 2010.
After differentiating small-cell lung cancer from non-small-cell lung cancer, a test will further subclassify non-small-cell lung cancer into squamous or nonsquamous. This test is being developed to leverage the company's new Fine Needle Aspirate (FNA) platform technology across several types of tests. The company aims to launch the extended lung cancer diagnostic in the second half of 2011.
The third test being developed by Rosetta Genomics is for bladder cancer. The aim of this test is to predict the risk of superficial bladder cancer becoming invasive. The target date for commercialization is late 2011.
Rosetta Genomics is a developer of microRNA-based molecular diagnostics. Its integrative research platform, combining bioinformatics and state-of-the-art laboratory processes, has led to the discovery of hundreds of biologically validated novel human microRNAs. The company is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools.
Related Links:
Rosetta Genomics
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Automatic CLIA Analyzer
Shine i6000
Latest Molecular Diagnostics News
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more
